{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Institut+de+Recherches+Internationales+Servier", "query": { "sponsor": "Institut de Recherches Internationales Servier" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 43, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Institut+de+Recherches+Internationales+Servier&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T15:32:09.614Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02074839", "title": "Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Acute Myeloid Leukemia (AML)", "Untreated AML", "Other IDH1-mutated Positive Hematologic Malignancies", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "AG-120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 291, "start_date": "2014-03-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074839" }, { "nct_id": "NCT04629443", "title": "Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukaemia" ], "interventions": [ { "name": "S 64315 (also referred as MIK665) and azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-02-17", "completion_date": "2023-08-25", "has_results": true, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629443" }, { "nct_id": "NCT06501625", "title": "Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation" ], "interventions": [ { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Durvalumab (for the first 8, 21-day, cycles)", "type": "DRUG" }, { "name": "Gemcitabine (for the first 8, 21-day, cycles)", "type": "DRUG" }, { "name": "Cisplatin (for the first 8, 21-day, cycles)", "type": "DRUG" }, { "name": "Durvalumab (starting from cycle 9)", "type": "DRUG" }, { "name": "Ivosidenib Recommended Combination Dose (RCD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2024-12-16", "completion_date": "2027-09-13", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 8, "location_summary": "Los Alamitos, California • Los Angeles, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06501625" }, { "nct_id": "NCT04164901", "title": "Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Grade 2 Glioma", "Residual Glioma", "Recurrent Glioma" ], "interventions": [ { "name": "Vorasidenib", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 331, "start_date": "2020-01-05", "completion_date": "2028-05", "has_results": true, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164901" }, { "nct_id": "NCT06116136", "title": "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "MSI-H/dMMR Gastroesophageal-junction Cancer", "MSI-H/dMMR Gastric Cancer" ], "interventions": [ { "name": "S095029", "type": "DRUG" }, { "name": "pembrolizumab 200 mg (KEYTRUDA ®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Servier Bio-Innovation LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2024-08-31", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 3, "location_summary": "Ocala, Florida • Noblesville, Indiana • Houston, Texas", "locations": [ { "city": "Ocala", "state": "Florida" }, { "city": "Noblesville", "state": "Indiana" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06116136" }, { "nct_id": "NCT05786924", "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Histiocytic Neoplasm", "Histiocytosis", "BRAF Gene Mutation", "BRAF V600E", "BRAF V600 Mutation", "BRAF Mutation-Related Tumors", "BRAF", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "Recurrent Lung Cancer", "Recurrent Lung Non-Small Cell Carcinoma", "NSCLC", "Solid Tumor", "Solid Carcinoma", "KRAS G12D", "KRAS G12V", "KRAS Mutation-Related Tumors", "NRAS Gene Mutation", "Thyroid Cancer", "Thyroid Carcinoma", "Colorectal Cancer", "Colorectal Carcinoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Brain Metastases", "Recurrent NSCLC", "KRAS G13C", "Acquired Resistance to KRAS G12C Inhibitor", "KRAS G12A", "KRAS G12F", "KRAS G12R", "KRAS G13D" ], "interventions": [ { "name": "S241656", "type": "DRUG" }, { "name": "FOLFOX6/FOLFOX7", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 554, "start_date": "2023-04-18", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 21, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05786924" }, { "nct_id": "NCT03715153", "title": "Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Autism Spectrum Disorder (ASD)" ], "interventions": [ { "name": "BUMETANIDE (S95008) for week 0 - 26", "type": "DRUG" }, { "name": "PLACEBO for week 0 - 26", "type": "DRUG" }, { "name": "Open-Label BUMETANIDE (S95008) for weeks 26 - 52", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "2 Years to 6 Years" }, "enrollment_count": 211, "start_date": "2018-10-04", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 1, "location_summary": "Staten Island, New York", "locations": [ { "city": "Staten Island", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03715153" }, { "nct_id": "NCT02073994", "title": "Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma", "Chondrosarcoma", "Glioma", "Other Advanced Solid Tumors" ], "interventions": [ { "name": "AG-120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2014-03-01", "completion_date": "2024-01-04", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073994" }, { "nct_id": "NCT01747538", "title": "Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uveitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Dose 1 gevokizumab", "type": "DRUG" }, { "name": "Dose 2 gevokizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XOMA (US) LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 281, "start_date": "2012-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-07-12", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 51, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 48 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01747538" }, { "nct_id": "NCT05162755", "title": "S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "S095029", "type": "DRUG" }, { "name": "S95029 and Sym021", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2021-10-15", "completion_date": "2026-05-05", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-05T15:32:09.614Z", "location_count": 4, "location_summary": "Grand Rapids, Michigan • Dallas, Texas • Houston, Texas + 1 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05162755" } ] }